pharma · Glioblastoma · Unresectable or metastatic soft tissue sarcoma
Philogen
Philogen S.p.A.
Philogen clinical programs — 18 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Loc. Bellaria, 35, Sovicille, SIENA 53018, IT
- Founded
- 1996
- Employees
- 180
- Programs
- 18
- Drugs
- 29
- Patents
- 0
Philogen projects
18 ClinicalTrials.gov programs sponsored by Philogen.
Philogen has 18 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Darleukin, Fibromun
Philogen S.p.A.
Malignant melanoma of the skin in patients with locally advanced and fully resectable melanoma with/without prior therapy and presence of injectable cutaneous and/or subcutaneous or nodal lesions
1 trial -
PH-L19TNFDOX2-03/16
Philogen S.p.A.
Unresectable or metastatic soft tissue sarcoma
1 trial -
Darleukin, Fibromun
Philogen S.p.A.
locally advanced basal cell carcinoma patients
1 trial -
Darleukin, Fibromun
Philogen S.p.A.
Patients with high-risk, locally advanced (non-metastatic, node negative, single or multifocal), Basal Cell Carcinoma (BCC) or cutaneous Squamous Cell Carcinoma (cSCC) amenable to intratumoral injection, not eligible to surgery or radiation therapy according to the evaluation of a local interdisciplinary tumor board or who refuse surgery or radiation therapy and for whom a histological evaluation is available according to international guidelines.
1 trial -
Fibromun, Darleukin
Philogen S.p.A.
Phase II, open label, multicentric, proof-of-principle basket trial in patients with malignant tumors of the skin amenable to intratumoral injection, and in a curative or neoadjuvant or palliative intention, including: • Basal cell carcinoma (BCC) • Cutaneous squamous cell carcinoma (cSCC) • Merkel cell carcinoma (MCC) • Keratoacanthoma (KA) • Malignant adnexal tumors of the skin (MATS) • Tumors from cutaneous T-cell lymphoma (CTCL) • Kaposi’s sarcoma (KS)
1 trial -
Fibromun, Darleukin
Philogen S.p.A.
Patients with locally advanced Basal Cell Carcinoma (LaBCC) amenable to intratumoral injection, who have progressed or intolerant to systemic treatment.
1 trial -
Fibromun, Darleukin
Philogen S.p.A.
Cutaneous Squamous Cell Carcinoma
1 trial -
Fibromun, Temozolomide SUN 100 mg hard capsules
Philogen S.p.A.
Glioblastoma
1 trial -
Lomustine "medac" 40 mg, Fibromun
Philogen S.p.A.
Glioblastoma
1 trial -
PH-ICKPD1-02/21
Philogen S.p.A.
Patients with diagnosis of unresectable clinical stage III or IV metastatic melanoma, with presence of injectable cutaneous, subcutaneous or nodal lesions and resistant to or progressing upon anti-PD1 immunotherapy
1 trial -
PH-L19TNFSARC-03/18
Philogen S.p.A.
Unresectable and/or metastatic soft-tissue sarcoma after failure of at least two prior systemic therapy regimens.
1 trial -
PH-ACP3GA-01/24
Philogen S.p.A.
Patients with prostate cancer with: -suspected metastasis who are candidates for initial definitive therapy -suspected recurrence based on elevated serum prostate-specific antigen (PSA) level (i.e., a progressive and confirmed serum PSA level > 0.2 ng/mL) -metastatic disease who might be candidates for treatment with 177Lu-labelled PSMA ligands
1 trial -
PH-ACP3GA-03/25
Philogen S.p.A.
Patients with prostate cancer with: - suspected metastasis who are candidates for initial definitive therapy - suspected recurrence based on elevated serum prostate-specific antigen (PSA) level (i.e., a progressive and confirmed serum PSA level > 0.2 ng/mL) - metastatic disease who might be candidates for treatment with 177Lu-labelled PSMA ligands
1 trial -
PH-CAIXGA-02/24
Philogen S.p.A.
Patients with suspected clear cell renal cell carcinoma (ccRCC)
1 trial -
PH-F8IL10INTRA-03/24
Philogen S.p.A.
Patients with Rheumatoid Arthritis (RA) who, despite treatment with stable doses (for at least 3 months) of disease-modifying antirheumatic drugs (DMARDs, conventional, biologic and/or targeted synthetic), present arthritis flare(s) suitable for intra-articular (IA) injection in a knee, shoulder, ankle, wrist or elbow.
1 trial -
PH-FAPLU-02-23
Philogen S.p.A.
Patients with advanced/metastatic FAP-positive tumors
1 trial -
PH-L19IL2CORK-01/25
Philogen S.p.A.
Advanced solid tumors, specifically: • metastatic clear cell renal carcinoma • proficient mismatch repair / microsatellite stable (pMMR/MSS), BRAF-V600E-mutant negative colorectal carcinoma • locally advanced or metastatic pancreatic adenocarcinoma
1 trial -
Safety and Early Signs of Efficacy of IL12-L19L19
Philogen S.p.A.
Advanced or metastatic carcinomas after previous immune checkpoint blockade therapy
1 trial
Frequently asked questions
How many clinical projects does Philogen have?
18 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.